Weight loss surgery has been shown to be five times more effective than the popular weekly injections GLP-1 receptor agonistsincluding semaglutide (such as Ozempic) and tilzepatide (such as Munjaro).
The discovery comes from a recent study presented this week at the American Society for Metabolic and Bariatric Surgery (ASMBS) 2025 Annual Science Conference held in Washington.
The researchers looked at “real world” electronic medical record data for 51,085 patients from NYU Langone Health and NYC Health + Hospitals.
Hairstylists and medical professionals check for temporary hair removal affecting Ozempic users
All patients had a body mass index (BMI) of at least 35.
They had experienced either Bariatric surgery I was prescribed (sleeve gastrectomy or roux en-y gastric bypass) or injectable semaglutide or tilzepatide between 2018 and 2024.
(Sleeve gastrectomy helps reduce stomach size Obese patients Lose weight; According to Mayo Clinic, gastric bypass involves rerouting the gastrointestinal tract and bypassing parts of the small intestine.
Patients who had one of the bariatric surgery lost an average of 58 pounds after 2 years, while patients who had been taking GLP-1 prescription medication for at least six months lost 12 pounds.
Low-calorie diets related to amazing mental health benefits, a new research show
Surgical results marked as 24% Total weight loss According to a press release from the study, 4.7% of drugs are compared with injectable drugs.
Those who took GLP-1 medication all year round showed more weight loss (7%), but that was still less than those who received one of the surgeries.
These results differ from those from clinical trials.
“While clinical trials show weight loss of 15% to 21% in GLP-1, in this study, Avery Brown, surgical resident at NYU Langone Health, said in a press release:
According to Brown, 70% of patients with GLP-1 prescription may discontinue treatment within a year.
“Participants with GLP-1 may need to adjust their expectations, or to stick more closely to treatment, or choose to choose. Metabolic and bariatric surgery To achieve the desired outcome,” he advised.
In future research, researchers plan to explore strategies to improve outcomes in patients taking GLP-1 and identify which patients are better candidates for injections and injections, Release said.
The prevalence of GLP-1 drugs is higher than that of bariatric surgery. Studies show that around 12% of Americans take GLP-1, while 6% are currently collecting them.
Click here to sign up for our health newsletter
However, more than half of patients stopped taking them after a year, and 72% abandoned them after two years, studies found.
According to ASMBS, only about 1% of patients who met the criteria for metabolic and bariatric surgery received one of these procedures in 2023.
I received this investigation I will grant funds From the National Center for Advancement of Translation Science at the National Institutes of Health (NIH).
Novo Nordisk, the maker of Ozempic and Wegovy, declined to request comment.
Visit us for more health articles www.foxnews.com/health
Fox News Digital also reached out to researchers and Eli Lilly, maker of Mounjaro and Zepbound.
